Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis in Liver Transplantation
Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis in Liver Transplantation
复制标题
DOI：
10.1016/j.cld.2017.08.015
复制
发表时间：
2018-02-01
影响因子：
5.1
通讯作者：
Chang, Charissa
中科院分区：
文献类型：
--
作者：
Carter, Danielle;Dieterich, Douglas T.;Chang, Charissa
由非酒精性脂肪性肝病/非酒精性脂肪性肝炎(NASH)引起的移植数量一直在逐渐增加，预计这将成为美国最常见的肝移植适应症。NASH患者表现出代谢综合征的许多特征，因此，术后心血管并发症和死亡率的风险更高。尽管如此，NASH患者的长期移植物和患者存活率与其他慢性肝病的原因相当。移植后代谢综合征是一种常见的情况，会增加移植肝脏脂肪变性的风险。
The number of transplants caused by nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NASH) has been progressively increasing and this is expected to become the most common indication for liver transplantation in the United States. Patients with NASH show many features of the metabolic syndrome and, as a result, are at higher risk for postoperative cardiovascular morbidity and mortality. Despite this, patients with NASH have long-term graft and patient survival rates comparable with other causes of chronic liver disease. Posttransplant metabolic syndrome is a common occurrence that increases the risk of steatosis in the graft liver.